Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, SBS

Lore IO Announces its Freemium Pre-Commercial Launch Analytics Solution to Help Emerging Biopharma Companies Better Plan Their First Product Launch


SUNNYVALE, Calif., April 14, 2021 /PRNewswire/ -- Lore IO, Inc., providers of an AI-powered common data model that enables faster data onboarding and unified data views, today announced the immediate availability of its freemium offering of Lore IO Pre-Commercial Launch Analytics. The offering helps emerging biopharma companies accelerate their pre-commercial launch planning by providing them with faster data onboarding, data transformation, and customizable dashboards. The announcement also marks the first pre-launch commercial analytics offering in Lore IO's Life Sciences Cloud Analytics solution, which has already proven successful for emerging biopharma companies with its commercial analytics package.

"Most emerging biopharma companies don't have the resources in early phases to onboard and analyze the data for their launch strategy. They rely on 3rd parties to answer their business questions with XLS or PPT files that become static and obsolete over time. We want to enable these small teams with the ability to analyze real-world patient data on their own so they can rapidly iterate on their launch strategy," said Janardan Prasad, Chief Business Officer and Head of Life Sciences at Lore IO. "Our freemium offering will give them the ability to overcome these challenges without investing time and resources while they are addressing the ever-changing market conditions prior to launch."

The Lore IO Pre-Commercial Launch Analytics solution expedites pre-launch planning in three key areas: Prescriber profiling, patient journey, and competitor analysis. Prescriber profiling enables teams to leverage insights from their data to discover the right prescribers in their target regions. Patient journey simplifies the analysis of historical data to better understand patients who are best suited for your product, what their unmet needs are, and what are the right touchpoints for them. Competitor analysis uses data to determine overall market share, regional product adoption, and shifts in market share between product classes and patient cohorts.

The freemium offering of Lore IO Pre-Commercial Launch Analytics solution is free for the first five (5) users and includes the onboarding and transformation of three (3) data sources, three (3) customizable prebuilt dashboards for Prescriber Profile, Patient Journey, and Competitor Analysis, and 30 days of customization based on the organization's KPIs and business requirements. After the first five users, companies may opt for pay-as-you-go, monthly pricing.

Tweet This: Lore IO announces new freemium offering of its Pre-Commercial Launch Analytics Package for emerging #biopharma companies. Freemium model includes onboarding and transformation of data sources, prebuilt dashboards, and customization. #commercialization

About Lore IO
Lore IO provides an AI-powered common data model that enables unified data views and faster data onboarding. The Company enables customers to unlock the full value of their data by empowering business users to collaborate on and use datasets that are initially hard to understand, reconcile, and blend. The Lore IO platform abstracts all the complex semantics of how the data is captured and joined together, enabling customers to instantly validate business logic in support of a wide range of use cases using a no-code approach. Lore IO's purpose-built analytics packages bring unprecedented self-serve business agility and have been proven to onboard data 10 times faster than traditional approaches. To learn more, follow the company on Twitter @teamloreio, follow on LinkedIn or visit https://www.getlore.io/.

Media Contact
Steven Dozen
Head of Marketing
Lore IO, Inc.
[email protected]
408.256.1521

 

SOURCE Lore IO


These press releases may also interest you

at 17:21
Chemistree Technology Inc. (US OTC: CHMJF) (the "Company" or "Chemistree"), is pleased to announce that the adjourned extraordinary meeting of the holders of the 10% senior unsecured convertible debentures of the Company (the "Debentures") was...

at 17:15
Summary Product: Counterfeit Viagra, 100 mg sildenafil tabletsIssue: Health products - Product safety, Unauthorized productWhat to do: Immediately stop using and safely dispose of this product. Consult your health care provider if you have taken this...

at 17:00
GBLT Corp. ("GBLT" or the "Company") announces that minority shareholders have approved the voluntary delisting (the "Delisting") of the common shares of the Company from the TSX Venture Exchange ("TSXV").  Approval for the delisting was received at...

at 17:00
L.A. Care Health Plan and Blue Shield of California Promise Health Plan today held a grand opening ceremony for their Community Resource Center (CRC) in West Los Angeles (West L.A.) at 11173 W. Pico Blvd in Los Angeles....

at 16:55
Veterinary Management Groups (VMG) is proud to...

at 16:45
Cronos Group Inc. ("Cronos" or the "Company") will hold its 2024 Annual Meeting of Shareholders on Thursday, June 20, 2024, at 11:00 a.m. ET. Cronos will be conducting the meeting in a virtual-only format via live audio webcast. Registered...



News published on and distributed by: